TACR1 and cancer: Currently, there are four NK-1R antagonists, namely L-733,060, L-732,138, CP-96,345, and the aprepitant drug (approved for chemotherapy-induced nausea/vomiting (CINV) in humans), which have demonstrated activity against cancer cells both in vitro and in vivo [16].